Frozen PRP treatment for thumb carpometacarpal joint osteoarthritis.

Safety evaluation of frozen PRP treatment for thumb carpometacarpal joint osteoarthritis.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTc030230742

Enrollment

Registered

2024-03-27

Start date

2024-10-29

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thumb carpometacarpal joint osteoarthritis Thumb carpometacarpal joint osteoarthritis,hand surgery,regenerative medicine, Platelet-Rich Plasma.

Interventions

Administration of cell processing products.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Thumb carpometacarpal joint osteoarthritis. 2) Thumb carpometacarpal joint osteoarthritis for whom pain relief is expected. 3) Have good systemic condition. 4) Number of platelet is over 1x10^5 /microliter. 5) 18 years and older. 6) Other,the investigator believes makes him/her suitable for participation in this clinical study.

Exclusion criteria

Exclusion criteria: 1) Have a history of Complicate malignant tumor. 2) Patients with other osteoarthritis of the hand on the same side as the thumb carpometacarpal joint osteoarthritis. 3) Patients with malignant tumor, precancerous lesion, or findings suspected of these on the same side as thumb carpometacarpal joint osteoarthritis. 4) Under 18 years of old. 5) Pregnancy, during breastfeeding, or possibility of pregnancy. 6) Other,the investigator believes makes him/her unsuitable for participation in the clinical study.

Design outcomes

Primary

Measure	Time frame
Evaluation of the safety of regenerative medical technology using the cell processing products. If below (1) or (2) occurs, at that point we will consider whether to continue enrollment in the study, treatment, or whole study. (1) If one or more adverse events grade 3 or higher of the Common Terminology Criteria for Adverse Events suspected to be related to the provision of regenerative medicine v5.0 Japanese translation JCOG version (abbreviation: CTCAE v5.0 -JCOG) occur. (2) In accordance with the Act on Securing the Safety of Regenerative Medicine, etc., if a "disease, injury, death, or infectious disease suspected to be caused by the provision of regenerative medicine, etc., listed in the regenerative medicine provision plan" occurs.	—

Measure

Time frame

Evaluation of the safety of regenerative medical technology using the cell processing products. If below (1) or (2) occurs, at that point we will consider whether to continue enrollment in the study, treatment, or whole study. (1) If one or more adverse events grade 3 or higher of the Common Terminology Criteria for Adverse Events suspected to be related to the provision of regenerative medicine v5.0 Japanese translation JCOG version (abbreviation: CTCAE v5.0 -JCOG) occur. (2) In accordance with the Act on Securing the Safety of Regenerative Medicine, etc., if a "disease, injury, death, or infectious disease suspected to be caused by the provision of regenerative medicine, etc., listed in the regenerative medicine provision plan" occurs.

—

Secondary

Measure	Time frame
(1) Analgesic effect of this treatment (improvement of VAS) (2) Patient subjective evaluation questionnaire	—

Countries

Japan

Contacts

Public ContactYasuko Kotake

Juntendo University

rm-gatekeeper@juntendo.ac.jp+81-3-3814-5672

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026